Description

Overview

Ipamorelin is a synthetic pentapeptide that acts as a growth-hormone secretagogue through the ghrelin/growth-hormone-secretagogue receptor (GHSR). Early pharmacology studies characterized it as relatively selective for growth-hormone release compared with older secretagogues that more strongly affected ACTH or cortisol. Research has focused on endocrine signaling, pharmacokinetics, growth-hormone pulse dynamics, and related metabolic or musculoskeletal endpoints.

How It Works

• GHSR activation: Ipamorelin activates the growth-hormone-secretagogue receptor in the hypothalamic-pituitary axis.
• Pulsatile GH release: The compound has been studied for its ability to provoke a growth-hormone pulse.
• Relative endocrine selectivity: Early studies examined effects on GH compared with ACTH, cortisol, and prolactin responses.

Research Areas

• Growth-hormone secretagogue pharmacology
• Pituitary signaling
• Endocrine pulse dynamics
• Bone and gastrointestinal experimental models

Research / Study Context

• Early human pharmacology: Healthy-volunteer studies measured concentration-time profiles and GH response.
• Preclinical models: Animal studies examined endocrine, bone, and gastrointestinal endpoints.

Key Research Findings

• Ipamorelin is a well-characterized experimental GHSR agonist.
• Human studies establish pharmacologic GH release, not broad claims of anti-aging or body-composition benefit.
• The compound is not FDA-approved as an Apex therapeutic product.

Related Research

• Sermorelin
• Tesamorelin
• CJC-1295 No DAC + Ipamorelin

Scientific Reference Starter Set

• Peptide Education Hub: Ipamorelin profile
• PubMed search: ipamorelin first selective growth hormone secretagogue
• PubMed search: ipamorelin pharmacokinetics growth hormone